Moderna, Inc. research snapshot
MRNA AI stock analysis currently reads Moderna, Inc. as a post-COVID platform biotech with a large cash balance, declining vaccine revenue, heavy R&D spending, and high option value in respiratory, oncology, rare disease, and latent-virus programs. At the July 8, 2026 data cutoff, MRNA traded near $79.77 with an implied market capitalization of about $31.65 billion. The AI view is not a simple buy signal because Moderna remains loss-making and the forecast depends on pipeline execution, commercial uptake, cash burn control, and regulatory events. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$79.77
Market cap
$31.65 billion
AI score
55 / 100
Rating
Speculative biotech recovery with strong cash but high pipeline risk
Trend status
Positive medium-term price recovery, still event-sensitive
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Moderna owns a validated mRNA platform, but current revenue is still concentrated in COVID and respiratory vaccines while the broader pipeline has not yet rebuilt durable earnings. | Medium |
| Moat | The moat comes from mRNA know-how, lipid nanoparticle delivery, manufacturing scale, regulatory experience, patents, and clinical data, but competitors and large pharma partners can contest each attractive market. | Medium |
| Management | CEO Stephane Bancel and the team deserve credit for rapid COVID execution, but capital allocation now depends on cutting cash burn while funding enough pipeline shots on goal. | Medium |
| Financial trend | FY2025 revenue was $1.944 billion with a $2.822 billion net loss, and Q1 2026 revenue was $108 million with cash and investments of $7.5 billion. | High |
| Valuation | At $79.77, MRNA traded near 16.3x FY2025 sales per share. Traditional P/E is not useful while EPS is negative, so valuation depends on cash runway and pipeline probability. | Medium |
| Technical trend | Price was above widely cited short, medium, and long moving averages, with resistance near the 52-week high area and event risk around earnings and clinical updates. | Medium |
| Risk level | Risk is high because vaccine demand, competition, R&D intensity, clinical readouts, approvals, and cash burn can change the equity story faster than reported revenue trends. | High |
| AI confidence | The descriptive research is well supported. The price forecast has lower confidence because a few pipeline and regulatory events can dominate fundamentals. | Medium |
| Investment certainty | Investment certainty is below business-data certainty. MRNA needs evidence that non-COVID products can create repeatable revenue before the thesis becomes high conviction. | Low-medium |
MRNA AI stock forecast
The MRNA AI stock forecast uses scenario ranges rather than a precise price prediction. The forced EPS/PE tool run showed negative EPS makes a normal P/E target unusable, so the practical forecast depends on cash burn, respiratory vaccine uptake, cancer vaccine data, rare disease progress, and whether investors assign value to the mRNA platform beyond COVID.
$105 to $125
More likely if RSV and COVID sales stabilize, flu and combination vaccine progress improves, INT oncology data strengthens with Merck, cash burn falls toward management targets, and the market values Moderna as a multi-product platform rather than a shrinking vaccine stock.
$70 to $90
More likely if cash remains ample but revenue recovery is gradual, respiratory demand stays seasonal, pipeline readouts are mixed, and investors wait for clearer 2027 to 2028 product contribution before expanding the multiple.
$45 to $60
More likely if COVID and RSV demand weaken further, clinical or regulatory timelines slip, cash burn remains elevated, competition limits pricing, or the market discounts the pipeline until approved non-COVID revenue becomes visible.
MRNA AI technical analysis
MRNA AI technical analysis is constructive but fragile as of the July 8, 2026 cutoff. Investing.com listed MRNA near $79.77 and above its 20-day, 50-day, 100-day, and 200-day moving averages, while MarketWatch listed a 52-week range of $23.15 to $83.12. That setup supports a recovery trend, but the stock is close enough to resistance that bad pipeline or earnings news can invalidate it.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $79.77 | Quote used for July 8, 2026 market cap, valuation, and technical analysis. |
| Near support | $71 to $73 | The 20-day moving average area near $72.15 is the first pullback zone to monitor. |
| Secondary support | $67 to $68 | The 50-day moving average area near $67.67 marks the next trend reference if short-term support fails. |
| Long-term support | $47 to $49 | The 200-day moving average near $48.42 is the major trend line. A break below it would challenge the recovery thesis. |
| Resistance | $83 to $84 | MarketWatch listed the 52-week high near $83.12, making this the first visible upside resistance zone. |
| Momentum | Recovery trend, event-sensitive | Price above key moving averages suggests momentum has improved, but biotech momentum can reverse around trial, FDA, guidance, or vaccine demand news. |
| Volume | High liquidity, news-driven spikes | Volume should be checked around earnings, ACIP or FDA events, oncology updates, and respiratory vaccine demand commentary. |
| Volatility | High biotech volatility | MRNA remains more volatile than a mature pharma stock because current earnings are negative and pipeline outcomes matter heavily. |
| Invalidation | Close below $67, then $48 | A decisive break below the 50-day average weakens the swing setup. A break below the 200-day average would force a full thesis review. |
MRNA AI trading strategy
The MRNA AI trading strategy is a rules-based framework for a volatile biotech platform stock. It is not personal advice and should be paired with live quotes, filings, position sizing, clinical calendars, FDA updates, and cash burn monitoring.
Watch for MRNA to hold above the 50-day moving average and challenge the $83 to $84 resistance zone with confirming volume and no negative vaccine or pipeline news.
A close below $67 should reduce confidence in the swing setup. A close below the 200-day moving average near $48 would require a full trend and thesis reset.
If MRNA pulls back toward the 20-day or 50-day moving average without a new clinical, regulatory, or cash burn problem, compare the price drop with fresh evidence on RSV, COVID, flu, combination vaccines, and oncology progress.
Do not treat every drop as technical noise. Pipeline delays, weak demand, or higher cash burn can turn a support level into a fundamental break.
Track quarterly cash and investments, operating loss, 2026 revenue guidance, respiratory vaccine sales, INT cancer vaccine milestones, rare disease trial data, regulatory decisions, and restructuring progress.
Reduce confidence if cash burn remains high while non-COVID revenue does not scale, or if pipeline value depends on repeated timeline extensions.
Investment research summary
Moderna tries to turn a programmable mRNA platform into approved medicines. Customers pay when the platform produces vaccines or therapeutics with clinical benefit, regulatory approval, manufacturing reliability, and acceptable reimbursement.
The moat is real but not settled. Moderna has mRNA know-how, delivery science, manufacturing experience, patents, and regulatory learning, yet Pfizer, BioNTech, GSK, Sanofi, Merck-partnered programs, and other biotech firms can compete where demand is attractive.
The thesis fails if respiratory vaccine demand keeps shrinking, if cash burn lasts longer than expected, if oncology or rare disease readouts disappoint, if regulators slow approvals, or if competitors produce better efficacy, safety, convenience, or price.
Management proved it could scale under extreme COVID urgency. The harder test is now discipline: narrowing the pipeline, reducing operating costs, preserving cash, and proving that non-COVID launches can support durable revenue.
mRNA remains part of a long-term biotech shift toward faster programmable medicines, cancer immunotherapy, and precision vaccines. The industry trend is favorable, but commercial adoption is uneven and clinical failure rates remain high.
With negative EPS, P/E does not provide a useful margin-of-safety signal. Investors are paying for cash runway, approved respiratory products, and pipeline option value, so the margin of safety improves only if cash burn falls and non-COVID proof points become harder to dispute.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MRNA price | $79.77 | MarketWatch quote snapshot | July 8, 2026 |
| Market capitalization | $31.65 billion, verified as $79.77 x 396.79 million shares | financial_rigor.py and StockAnalysis market cap data | July 8, 2026 |
| FY2025 revenue | $1.944 billion | Moderna FY2025 results and Macrotrends cross-check | July 8, 2026 |
| FY2025 net loss | $2.822 billion net loss | Moderna FY2025 results and StockTitan release cross-check | July 8, 2026 |
| Q1 2026 revenue | $108 million | Moderna Q1 2026 financial results | July 8, 2026 |
| Cash and investments | $7.5 billion at March 31, 2026 | Moderna Q1 2026 release, BioSpace, and Yahoo Finance summary | July 8, 2026 |
| Shares outstanding | 396.79 million shares used for market cap verification | StockAnalysis shares outstanding data | July 8, 2026 |
| Valuation math | P/S about 16.28x; P/E not meaningful because EPS is negative | financial_rigor.py valuation verification | July 8, 2026 |
| Moving averages | Price above 20-day, 50-day, 100-day, and 200-day moving averages | Investing.com technical summary | July 8, 2026 |
| 52-week range | $23.15 to $83.12 | MarketWatch quote and range data | July 8, 2026 |
This MRNA AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, technical data, and third-party sources as of July 8, 2026. They may be wrong, incomplete, or outdated after new earnings, vaccine demand updates, clinical data, regulatory decisions, cash burn changes, market moves, or macro conditions.
